The short version of 胰高血糖素受体 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Appearance | Lyophilized powder | White to off-white solid |
| Storage temperature | Approximately -20 °C | Dry, dark, desiccated |
| Solubility | Water-soluble peptide | Depends on sequence and buffer |
| Identity method | Mass spectrometry | Confirms expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main-peak proportion |
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
Ribonuclease P (EC 3.1.26.5, RNase P) is a type of ribonuclease which cleaves RNA. RNase P is unique from other RNases in that it is a ribozyme – a ribonucleic acid that acts as a catalyst in the same way that a protein-based enzyme would. Its function is to cleave off an extra, or precursor, sequence of RNA on tRNA molecules. Further, RNase P is one of two known multiple turnover ribozymes in nature (the other being the ribosome), the discovery of which earned Sidney Altman and Thomas Cech the Nobel Prize in Chemistry in 1989: in the 1970s, Altman discovered the existence of precursor tRNA with flanking sequences and was the first to characterize RNase P and its activity in processing of the 5' leader sequence of precursor tRNA. Its best characterised enzyme activity is the generation of mature 5′-ends of tRNAs by cleaving the 5′-leader elements of precursor-tRNAs. Cellular RNase Ps are ribonucleoproteins. The RNA from bacterial RNase P retains its catalytic activity in the absence of the protein subunit, i.e. it is a ribozyme. Similarly, archaeal RNase P RNA has been shown to be weakly catalytically active in the absence of its respective protein cofactors. Isolated eukaryotic RNase P RNA has not been shown to retain its catalytic function, but is still essential for the catalytic activity of the holoenzyme. Although the archaeal and eukaryotic holoenzymes have a much greater protein content than the bacterial ones, the RNA cores from all three lineages are homologous—the helices corresponding to P1, P2, P3, P4, and P10/11 are common to all cellular RNase P RNAs.
2CmO2 + H2 → Cm2O3 + H2O Also, a number of ternary oxides of the type M(II)CmO3 are known, where M stands for a divalent metal, such as barium. Thermal oxidation of trace quantities of curium hydride (CmH2–3) has been reported to give a volatile form of CmO2 and the volatile trioxide CmO3, one of two known examples of the very rare +6 state for curium. Another observed species was reported to behave similar to a supposed plutonium tetroxide and was tentatively characterized as CmO4, with curium in the extremely rare +8 state; but new experiments seem to indicate that CmO4 does not exist, and have cast doubt on the existence of PuO4 as well.
The duplication events provided material for neofunctionalization to create the novel toxin genes, while gene loss influenced speciation and helped lead to such a wide variety of "chemical cocktails" in rattlesnake venoms. The prevailing theory for the driving force of this evolution is directional selection, where efficacy on prey is selected for. Diversity in prey leads to less specificity in toxins, while highly specialized toxins are more likely to develop when there are few key prey species. However, recently, balancing selection has been indicated to better explain the maintenance of adaptive genetic diversity in venom-related genes, potentially allowing for the rattlesnakes to better keep up in the evolutionary arms race with their prey. Older snakes possess more potent venom, and larger snakes are frequently capable of storing larger volumes of it.
However, the National Gazette had previously run articles detailing the struggling conditions in Sichuan; exacerbated by heavy war taxes and drought, desperate peasantry were allegedly eating grass, bark, and even resorting to cannibalism. Liu Wenhui admitted himself that anti-government unrest had occurred in Rongxian and Yibin. The National Gazette reported that students from Rongxian had submitted a petition listing the exorbitant taxes imposed on them; many of Liu Wenhui's fees were similar or even identical to those levied by Liu Chengxun, including the 5,000-yuan "revolution tax". Similar complaints and petitions to Liu Wenhui from local residents were recorded denouncing Liu Wencai's taxation regime in 1925 and around 1927. According to the 1927 letter, Liu Wencai had collaborated with Tan Xiaolou and become director of taxation bureaus. Liu Wencai exacted many inventive forms of payment, including a "flower tax" for prostitutes, fees to pay for wounded soldiers, and several other miscellaneous taxes on such varied articles as hoes, toilets, stamps, and clothing. Liu Wencai had also engaged in speculation, monopolizing the supply of various medicinal herbs to sell them at high prices. After the 24th Army launched an auction of public properties in 1927, Liu Wencai used several different aliases in order to purchase the bulk of the real estate for sale. Slogans targeting Liu Wencai had also appeared in the streets of Yibin. However, Liu Wenhui did not take action against his brother.
Sources: en.wikipedia.org
A¹ – 2-aminoisobutyric acid (Aib). L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine). S³ – L-serinamide (L-serine with the carboxylic acid group replaced with a carboxamide). K⁴ – L-lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides). Retatrutide is synthetically engineered and produced using solid-phase peptide synthesis (SPPS). This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone. After the backbone is synthesized, the molecule is cleaved chemically, then purified. Lipidation modifications also occur, meaning a fatty-acid side chain is added to promote reversible binding to albumin. This modification allows for a longer drug half-life, raising compliance as it enables once-weekly dosing.
== Side effects == The side effects of trimipramine have been said to be similar to those of other tertiary amine TCAs, with a preponderance of anticholinergic and sedative effects. However, trimipramine has also been said to be associated with a different side effect profile compared to other TCAs and in general with fewer side effects, chiefly due to its lack of norepinephrine reuptake inhibition and relatively lower anticholinergic effects (although it is still a potent anticholinergic). Somnolence is the most common side effect of the drug. Dry mouth is the most common anticholinergic side effect, but others like constipation, urinary retention, and blurred vision are also present. Such effects, in any case, may be treated with bethanechol. It is described as being associated with minimal or no orthostatic hypotension, at least in comparison to clomipramine, in spite of its potent and comparable activity as an alpha-1 blocker. However, it has also been said to have a rate of orthostatic hypotension similar to that of other TCAs. Trimipramine is said to be less epileptogenic than other TCAs, although seizures have still been reported in association with it. It is also less cardiotoxic than other TCAs and cardiotoxicity is said to be minimal, with a "very favorable profile". Heavy exposure to any tricyclic antidepressants was associated with an elevated rate ratio for breast cancer 11–15 years later.
== Predictive genetic testing == Due to the high cost of immunotherapy and the reluctance of insurers to pre-authorize treatment, various genetic and molecular tests have been developed to predict therapeutic response. Three major biomarkers are currently FDA-approved and widely used in clinical practice: (1) programmed death-ligand 1 (PD-L1) expression, (2) microsatellite instability (MSI) or mismatch repair deficiency (dMMR), and (3) tumor mutational burden (TMB). PD-L1 expression, detected via immunohistochemistry, may indicate which tumors are more likely to respond to immune checkpoint inhibitors by revealing the presence of proteins that help cancer cells evade immune surveillance. However, its predictive value is limited by variability in expression across tumor types, locations, and testing platforms. MSI and dMMR, identified through molecular or immunohistochemical testing, indicate a deficiency in DNA repair mechanisms and are associated with high mutation rates that may increase tumor immunogenicity. These biomarkers have been approved to guide the use of checkpoint inhibitors in several cancer types. TMB, measured by next-generation sequencing, quantifies the total number of somatic mutations in a tumor genome. High TMB has been associated with improved responses to immunotherapy, although its clinical utility remains controversial and context-dependent. As of 2023, reliance on TMB as a selection criterion for immunotherapy was still debated in the scientific community.
Sources: en.wikipedia.org
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.
Lower temperatures slow chemical degradation reactions such as hydrolysis and oxidation. Light and moisture protection addresses additional pathways that can alter the molecule during storage.
A purity figure describes the proportion of the detected signal attributed to the main peak under a specific method. Different methods can produce different values for the same sample.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.